January 25, 2019 8:26am

What degree of momentum follows through ... especially on a Friday?

The IBB, XBI, XLV and IWM are up - all together, for once!

Pre-open indication: 1 BUY and 3 TRADEs

 

I answer one question, in which company should investors put, keep and commit their money!

I make a commitment to provide need-to-know “facts in evidence” as equity’s volatility is one tactical signal for stocks.

 

U.S. stock index futures are up

Dow futures are UP +0.72% (+175 points) and NASDAQ futures are UP +1% (+67 points)

 

U.S. stock index futures rose ahead of Friday's open, as investors geared up for another batch of corporate earnings;

European stocks edge higher despite US-China trade fears;

Asian stocks gain despite US-China trade jitters

 

Friday’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +0.33% UPSIDE

The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.71% UPSIDE

The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.1% UPSIDE

The iShares Russell 2000 (IWM) is indicating a POSITIVE +0.05% UPSIDE

 

Henry’omics:

Another week draws to a close, as LOW volume defines momentum to the upside and downside.

Stock prices have rallied during the government shutdown, but that could end soon, as economic impact widens. But it has hurt consumer and business sentiment, and if continues another few weeks, it will start to have a measurable impact on the economy, and when investors see that impact, stocks will get hit,”

TGIF, my brain needs to shut down after Monday’s holiday, Tuesday and Wednesday’s – NEGATIVE, and Thursday’s - POSITIVE closes after last week’s 3 POSITIVE (Friday, Wednesday and Tuesday) and 2 NEGATIVE (Thursday and Monday)closes – patterns or just flip-flops?

 

Thursday’s evening post, “sector jumps making up for ground lost as the risk appetite dwindles or does it? … Stay buckled-up for more sector volatility.”

I also stated, “The RegMed sector suffers the tourist routine … most traders hear a piece of news, get excited or contemplate a pumping to decide to buy and a dumping to sell.”

Thursday’s night’s percentage (%) indicators:  creaky

  • Review the range of the 31 upside from +0.29% (STML) to +11.46% (CUR +$0.0384) while the 12 downside ranged from -0.09% (RGNX) to -2.56% (VYGR) with 2 flat close (BCLI and ADRO).

Volume stat:  extremely low

  • 4 out of the 31 upside had higher (than the 3 month average) volume
  • 0 out of the 12 downside experienced greater volume (than the 3 month average) volume

Running the month:

In 16 sessions in January – there was 10 positive closes, 1 holiday and 6 negative closes – so far!

 

Companies in my headlights – It’s your decision; I provide an idea and context:

Cellectis (CLLS) closed down again -$0.16 to $15.53 after Wednesday’s -$0.19 to $15.69 following Tuesday’s -$0.86 to $15.88. OVERSOLD – Maintaining BUY;

CRISPRS Therapeutics (CRSP) closed up +$0.89 to $32.29 after Wednesday’s -$1.68 to $31.40, Tuesday’s -$4.05 to $33.0-8 and last Friday’s +$1.25 to $37.13. There is a negative -$0.43 or -1.33% aftermarket indication – TRADE;

Editas Medicine (EDIT) closed up +$1.23 to $21.33 after Wednesday’s  -$0.85 to $20.10, Tuesday’s -$5.19 to $20.95 (after news of their CEOs resignation following the CFO and CMO leaving) and last Friday’s -$0.07 to $26.14. There is a negative -$0.58 or -2.72% aftermarket indication –Maintaining BUY;

Intellia Therapeutics (NTLA) closed up +$0.60 to $14.38 after Wednesday’s -$0.38 to $13.68, Tuesday’s -$1.04 to $14.16 and last Friday’s +$0.28 to $15.20. There is a NO aftermarket indication – TRADE;

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.